Monday, May 3
1:30 - 2:30pm EDT
Katherine A. High, MD
Professor Emerita, Perelman School of Medicine of the University of Pennsylvania
President, Therapeutics, Asklepios BioPharmaceutical
Co-founder and former president and head of R&D, Spark Therapeutics
About Katherine High, MD
Katherine A. High, MD, is president of AskBio, Therapeutics where she is responsible for driving the strategic direction and execution of the company’s preclinical and clinical programs. She is also a member of the AskBio Board of Directors.
Prior to this, High co-founded Spark Therapeutics, Inc., where she served as president and head of Research and Development (2014 - 2020), and was a member of the Board of Directors from 2014 - 2019. At Spark, High gained approval of the first gene therapy for a genetic disease in the U.S., and the first AAV product. She also led the Spark development programs for hemophilia B and hemophilia A, both of which earned FDA Breakthrough Therapy Designation.
From 2004 to 2014, High was a professor at the Perelman School of Medicine at the University of Pennsylvania, an investigator of the Howard Hughes Medical Institute and the director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia. She completed a five-year term (2000 - 2005) on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy.
High holds an AB in chemistry from Harvard University, an MD from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary MA from The University of Pennsylvania.
She is the author of more than 200 scientific papers and is an elected member of the National Academy of Medicine (US), the American Academy of Arts and Sciences, and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (London). High currently serves on the Board of Directors of CRISPR Therapeutics.